VANGUARD GROUP INC - 31 Dec 2024 SCHEDULE 13G/A Report for Zentalis Pharmaceuticals Inc Common Stock (ZNTL)

Filing Manager
VANGUARD GROUP INC
Reporting Manager
The Vanguard Group
Security
Zentalis Pharmaceuticals Inc Common Stock
Symbol
ZNTL
Shares outstanding
71,268,845 shares
Disclosed Ownership
3,271,240 shares
Ownership
4.6%
Form type
SCHEDULE 13G/A
Filing time
31 Jan 2025, 10:09:52 UTC
Date of event
31 Dec 2024
SEC
View on sec.gov

Quoteable Key Fact

"VANGUARD GROUP INC disclosed 4.6% ownership in Zentalis Pharmaceuticals Inc Common Stock (ZNTL) on 31 Dec 2024."

Quick Takeaways

  • VANGUARD GROUP INC filed SCHEDULE 13G/A for Zentalis Pharmaceuticals Inc Common Stock (ZNTL).
  • Disclosed ownership: 4.6%.
  • Date of event: 31 Dec 2024.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 31 Jan 2025, 10:09.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (1)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
The Vanguard Group 4.6% 3,271,240 0 25,056 Ashley Grim Head of Global Fund Administration